Sign In
Buy CAPR
$24.08
+0.280 (+1.18%)
At Close: Jun 30, 2026
What's Going On With Capricor Therapeutics Stock On Friday?
02:06pm, Friday, 26'th Jun 2026
Capricor Therapeutics Inc. (NASDAQ:CAPR) stock is trading lower on Friday, down by 13%.
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026–
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ
Caprock Announces Closing of Private Placement
05:47pm, Friday, 19'th Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 19, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce that it has closed its previously announced non-brokered pri
Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.
04:32pm, Wednesday, 17'th Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 17, 2026) - Frank Guillemette (the "Acquiror") announces that, on June 12, 2026, he acquired an aggregate of 200,000 common shares in the capital of Caprock Mi
Caprock Announces Proposed Private Placement
06:02pm, Friday, 12'th Jun 2026
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock" or the "Company") is pleased to announce a proposed non-brokered private placement offering of up to 6
Toronto, Ontario--(Newsfile Corp. - June 12, 2026) - Caprock Mining Corp. (CSE: CAPR) ("Caprock", or the "Company") is pleased to announce high-grade assay results for the final three drill holes fro
Capricor Therapeutics Eyes FDA Approval Path for Duchenne Cell Therapy
09:04am, Thursday, 11'th Jun 2026
Capricor Therapeutics NASDAQ: CAPR executives said the company is in active discussions with the U.S. Food and Drug Administration as it works toward a potential approval decision for deramiocel, its
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:52pm, Wednesday, 10'th Jun 2026
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics to Present at Upcoming Investor Conferences
09:25am, Monday, 08'th Jun 2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
04:43am, Wednesday, 03'rd Jun 2026
Capricor is rated a speculative Buy ahead of its August 22 PDUFA for deramiocel in Duchenne muscular dystrophy. Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac end
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
10:50pm, Tuesday, 12'th May 2026
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics Q1 Earnings Call Highlights
06:08pm, Tuesday, 12'th May 2026
Capricor Therapeutics NASDAQ: CAPR said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th May 2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
07:01am, Sunday, 10'th May 2026
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing.
